BioLineRx (BLRX) Income towards Parent Company (2011 - 2026)

BioLineRx's Income towards Parent Company history runs 14 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• In Q4 2025, Income towards Parent Company rose 29.84% year-over-year to -$2.2 million; the TTM figure through Dec 2025 stood at -$2.0 million (up 78.03% YoY), while the FY2025 annual figure was -$1.2 million, up 87.26% from the prior year.
• Income towards Parent Company for Q4 2025 stood at -$2.2 million, down from -$977000.0 in the prior quarter.
• The five-year high for Income towards Parent Company was $5.1 million in Q1 2025, with the low at -$23.1 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$6.0 million (2021), against an average of -$5.5 million.
• Peak annual rise in Income towards Parent Company reached 836.64% in 2025, while the deepest fall reached 533.92% in 2025.
• BioLineRx's Income towards Parent Company stood at -$6.1 million in 2021, then declined by 8.15% to -$6.6 million in 2022, then sank by 247.56% to -$23.1 million in 2023, then jumped by 86.18% to -$3.2 million in 2024, then advanced by 29.84% to -$2.2 million in 2025.
• Business Quant data shows BLRX's Income towards Parent Company at -$2.2 million in Q4 2025, -$977000.0 in Q3 2025, and -$3.9 million in Q2 2025.